UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches

International journal of molecular sciences, 2022-09, Vol.23 (18), p.10616

Lugnier, Claire

2022

Link zum Volltext

Verfügbarkeit prüfen

PDE inhibitors: a new approach to treat metabolic syndrome?

Current opinion in pharmacology, 2011-12, Vol.11 (6), p.698-706

Lugnier, Claire

2011

Link zum Volltext

Verfügbarkeit prüfen

Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs

Current pharmaceutical design, 2010-03, Vol.16 (9), p.1114

2010

Link zum Volltext

Verfügbarkeit prüfen

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents

Pharmacology & therapeutics (Oxford), 2006-03, Vol.109 (3), p.366-398

Lugnier, Claire

2006

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Pharmacological Evaluation of N‑Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase‑4 Inhibitors

Journal of medicinal chemistry, 2012-09, Vol.55 (17), p.7525-7545

2012

Link zum Volltext

Verfügbarkeit prüfen

The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure

Journal of clinical medicine, 2019-10, Vol.8 (10), p.1746

2019

Link zum Volltext

Verfügbarkeit prüfen

Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells

PloS one, 2015-12, Vol.10 (12), p.e0145291-e0145291

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families

Cellular signalling, 2017-11, Vol.39, p.55-65

2017

Link zum Volltext

Verfügbarkeit prüfen

NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants

Frontiers in pharmacology, 2020-08, Vol.11, p.1266-1266

2020

Link zum Volltext

Verfügbarkeit prüfen

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

British journal of pharmacology, 2012-03, Vol.165 (5), p.1288-1305

2012

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, Pharmacological Evaluation and Vascular Effects of Delphinidin Analogues

Current pharmaceutical design, 2018-01, Vol.24 (46), p.5580

2018

Link zum Volltext

Verfügbarkeit prüfen

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II

PloS one, 2010-12, Vol.5 (12), p.e14227-e14227

2010

Link zum Volltext

Verfügbarkeit prüfen

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor

PloS one, 2012-01, Vol.7 (1), p.e28899-e28899

2012

Link zum Volltext

Verfügbarkeit prüfen

Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4

Thrombosis and haemostasis, 2004-09, Vol.92 (3), p.634

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of the Phosphodiesterase 5 Inhibitor Sildenafil on Ischemia-Reperfusion-Induced Muscle Mitochondrial Dysfunction and Oxidative Stress

Antioxidants, 2019-04, Vol.8 (4), p.93

2019

Link zum Volltext

Verfügbarkeit prüfen

PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking

Biochemical pharmacology, 2021-03, Vol.185, p.114431-114431, Article 114431

2021

Link zum Volltext

Verfügbarkeit prüfen

VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors

Thrombosis and haemostasis, 2003-08, Vol.90 (2), p.334

2003

Link zum Volltext

Verfügbarkeit prüfen

Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

Pharmacology & therapeutics (Oxford), 2020-04, Vol.208, p.107475-107475, Article 107475

2020

Link zum Volltext

Verfügbarkeit prüfen

Study of the mechanisms involved in the vasorelaxation induced by (−)‐epigallocatechin‐3‐gallate in rat aorta

British journal of pharmacology, 2006-02, Vol.147 (3), p.269-280

2006

Link zum Volltext

Verfügbarkeit prüfen

Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (±)-naringenin

Planta medica, 2005-02, Vol.71 (2), p.99-107

2005

Link zum Volltext

Verfügbarkeit prüfen

Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2

Biochemical pharmacology, 2003-02, Vol.65 (4), p.669-675

2003

Link zum Volltext

Verfügbarkeit prüfen

Cyclic nucleotide phosphodiesterase (PDE) implication in lupus erythematosus: Effect of a new PDE4 inhibitor

Immunome research, 2017-01, Vol.13 (S1), p.44

Lugnier, Claire

2017

Link zum Volltext

Verfügbarkeit prüfen

New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam

Bioorganic & medicinal chemistry letters, 2011-11, Vol.21 (21), p.6567-6572

2011

Link zum Volltext

Verfügbarkeit prüfen

NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice

Biochimica et biophysica acta. Molecular basis of disease, 2021-03, Vol.1867 (3), p.166019-166019, Article 166019

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin

Naunyn-Schmiedeberg's archives of pharmacology, 2004-12, Vol.370 (6), p.452-463

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(145)

Sprache

Englisch
(144)
Japanisch
(26)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Animals
(95)
Life Sciences & Biomedicine
(95)
Pharmacology & Pharmacy
(58)
Biological And Medical Sciences
(48)
Humans
(45)
Phosphodiesterase Inhibitors - Pharmacology
(44)
Life Sciences
(41)
Male
(37)
Rats
(35)
Medical Sciences
(32)
Pharmacology. Drug Treatments
(30)
3',5'-Cyclic-Amp Phosphodiesterases - Antagonists & Inhibitors
(25)
3',5'-Cyclic-Amp Phosphodiesterases - Metabolism
(25)
Cyclic Amp - Metabolism
(25)
Cattle
(24)
Biochemistry, Molecular Biology
(20)
Cyclic Gmp - Metabolism
(20)
Phosphodiesterase
(20)
In Vitro Techniques
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches

PDE inhibitors: a new approach to treat metabolic syndrome?

Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents

Design, Synthesis, and Pharmacological Evaluation of N‑Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase‑4 Inhibitors

The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure

Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells

Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families

NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

Design, Synthesis, Pharmacological Evaluation and Vascular Effects of Delphinidin Analogues

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor

Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4

Effect of the Phosphodiesterase 5 Inhibitor Sildenafil on Ischemia-Reperfusion-Induced Muscle Mitochondrial Dysfunction and Oxidative Stress

PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking

VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors

Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

Study of the mechanisms involved in the vasorelaxation induced by (−)‐epigallocatechin‐3‐gallate in rat aorta

Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (±)-naringenin

Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2

Cyclic nucleotide phosphodiesterase (PDE) implication in lupus erythematosus: Effect of a new PDE4 inhibitor

New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam

NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice

Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin

Suchergebnisse filtern